While valuations across the pharmaceutical industry have soared this year -- with shares of diversified giants like Merck (NYSE:MRK) and Pfizer up significantly -- Bristol-Myers Squibb (NYSE:BMY) in particular has been on a tear recently. In the last 12 months, its shares are up a whopping 40%. However, despite all of the promising drugs that the company is developing in clinical trials, is there any upside left in this stock today? In the following video, analysts David Williamson and Max Macaluso discuss three reasons to consider selling Bristol-Myers.
David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.